| Item type |
文献 / Documents(1) |
| 公開日 |
2019-03-05 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.18632/oncotarget.15385 |
|
|
言語 |
ja |
|
|
関連名称 |
10.18632/oncotarget.15385 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers |
|
言語 |
en |
| 著者 |
イワモト, タカユキ
片桐, 豊雅
ニイクラ, ナオキ
ミヨシ, ユウイチロウ
コウチ, マリコ
ノガミ, トモヒロ
シエン, タダヒコ
モトキ, タカユキ
タイラ, ナルト
オオモリ, マサコ
トクダ, ユタカ
フジワラ, トシヨシ
ドイハラ, ヒロヨシ
Gyorffy, Balazs
マツオカ, ジュンジ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.
Results: Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively).
Materials and Methods: Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.
Conclusions: IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
short-term hormone therapy |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
IHC Ki67 |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
genomic marker |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
breast cancer |
| 書誌情報 |
en : Oncotarget
巻 8,
号 16,
p. 26122-26128,
発行日 2017-02-16
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
19492553 |
| 出版者 |
|
|
出版者 |
Impact Journals, LLC |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
Copyright: Iwamoto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| EID |
|
|
識別子 |
324026 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
onc_8_16_26122.pdf (762 KB)
.png)
